Expert Interview
A look at Mersana Therapeutics' first-in-class NaPi2b-targeting Antibody Drug Conjugate, UpRi (upifitamab rilsodotin) with an ovarian cancer specialist
Ticker(s): MRSNInstitution: Massachusetts General Hospital
- Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School & Chief Medical Officer of the Massachusetts General Physicians Organization.
- Currently manages 450 patients with ovarian cancer and has experience prescribing ADC's
- PI of clinical trials evaluating novel therapies in the treatment of ovarian cancer, as well as the design of a novel device for delivery of intra-peritoneal catheter.
What are your thoughts on the use and potential of antibody-drug conjugates (ADC) in ovarian cancer?
Added By: user76yu710zWhat are your thoughts on the ongoing Phase 2 UPLIFT trial?
Added By: user76yu710zIn your opinion, is Mersana's UpRi highly differentiated from other ADC's available or in development?
Added By: user76yu710zAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
